ASCO 2022: Focus on Metastatic Breast Cancer

Investigational Treatment Combo Produces Responses in HER2-Positive Metastatic Breast Cancer
Investigational Treatment Combo Produces Responses in HER2-Positive Metastatic Breast Cancer
Kerri FitzgeraldASCO 2022 | April 11, 2023
Pyrotinib, a second-generation, irreversible anti-human epidermal growth factor receptor 2 (HER2) tyrosine kinase ...
These Factors Predict Survival in Patients With HER2-Positive Breast Cancer and Brain Metastases
These Factors Predict Survival in Patients With HER2-Positive Breast Cancer and Brain Metastases
Kerri FitzgeraldASCO 2022 | April 11, 2023
Research presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting indicated that the following ...
Addition of Ribociclib to Endocrine Therapy Improves Survival in Metastatic Breast Cancer
Addition of Ribociclib to Endocrine Therapy Improves Survival in Metastatic Breast Cancer
Kerri FitzgeraldASCO 2022 | April 11, 2023
The phase II MAINTAIN trial evaluated the efficacy of adding ribociclib to endocrine therapy in patients with hormone ...
“Practice-Changing” Results Seen With Targeted Therapy in HER2-Low Metastatic Breast Cancer
“Practice-Changing” Results Seen With Targeted Therapy in HER2-Low Metastatic Breast Cancer
Kerri FitzgeraldASCO 2022 | April 11, 2023
Results of the DESTINY-Breast04 study, presented at the 2022 American Society of Clinical Oncology (ASCO) Annual ...
Advertisement
Advertisement
Advertisement
Advertisement

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    About Us

    Editorial Policy

    Advertising

    Connect

    Contact Us

    eNewsletters

    Contribute

    Career Center

    Our Network

    MashupMD

    Blood Cancers Today

    Cancer Nursing Today

    GU Oncology Now

    Urban Health Today

    © 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.

    Terms of Use | Privacy Policy |